Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies

References

• Rosenberg SA. Follicular lymphoma revisited. J Clin Oncol 2008;26:515–516.
   PubMed Web of Science ®Google Scholar
• Fisher RI, LeBlanc M, Press OW, . New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–8452.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, . Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, . Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579–4586.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, . Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706–714.
   PubMed Web of Science ®Google Scholar
• Rohatiner AZ, Gregory WM, Peterson B, . Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215–2223.
   PubMed Web of Science ®Google Scholar
• Baldo P, Rupolo M, Compagnoni A, . Interferon-alpha for maintenance of follicular lymphoma. Cochrane Database Syst Rev 2010;(1):CD004629.
   Google Scholar
• Steward WP, Crowther D, McWilliam LJ, . Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 1988;61:441–447.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Shaffer DW, . Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088–1095.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, . Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416–4423.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Schmitz SF, Utiger U, . Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010;28:4480–4484.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, . Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, . Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853–2858.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, . Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003–4008.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Burris HA 3rd, Morrissey LH, . Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000;95:3052–3056.
   PubMed Web of Science ®Google Scholar
• Ardeshna K, Qian W, Smith P, . An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood 2010;116(Suppl. 1): Abstract 6.
   Google Scholar
• Kahl BS. Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). Clin Lymphoma Myeloma 2006;6:423–426.
   PubMedGoogle Scholar
• Hochster H, Weller E, Gascoyne RD, . Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607–1614.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR, . Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202–1208.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Leibovici L, . Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248–255.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Morrison V, Hong F, Habermann T, . R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large B-cell lymphoma (DLBCL) patients (pts): long-term follow-up of Intergroup E4494/C9793. Blood 2010;116(Suppl. 1): Abstract 589.
   Google Scholar
• Rummel M, Niederle N, Maschmeyer G, . Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114(Suppl. 1): Abstract 405.
   Google Scholar
• Hirt C, Schuler F, Dolken G. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab. Semin Cancer Biol 2003;13:223–231.
   PubMed Web of Science ®Google Scholar
• Ladetto M, Magni M, Pagliano G, . Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006;12:1270–1276.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol 2003;30:9–15.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH, . Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746–1751.
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA, . Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995–1001.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Grow WB, Pusateri A, . Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005;23:1096–1102.
   PubMed Web of Science ®Google Scholar
• Kahl B, Williams M, Hong F, . Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT). Blood 2007;110(Suppl. 1): Abstract 3420.
   PubMed Web of Science ®Google Scholar
• Taverna C, Bassi S, Hitz F, . Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03. Blood 2010;116(Suppl. 1): Abstract 1802.
   Google Scholar
• Kasteng F, Erlanson M, Hagberg H, . Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol 2008;47:1029–1036.
   PubMed Web of Science ®Google Scholar
• Deconinck E, Miadi-Fargier H, Pen CL, . Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics 2010;28:35–46.
   PubMed Web of Science ®Google Scholar
• Rao A, Kelly M, Musselman M, . Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008;50:822–825.
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, . Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834–4840.
   PubMed Web of Science ®Google Scholar
• Li X, Lin Q, Dong M, . Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma 2010;51:1678–1685.
   PubMed Web of Science ®Google Scholar
• Matsue K, Kimura S, Takanashi Y, . Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010;116:4769–4776.
   PubMed Web of Science ®Google Scholar
• Pei SN, Chen CH, Lee CM, . Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255–262.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, . Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27: 605–611.
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998–1005.
   PubMed Web of Science ®Google Scholar
• Bermudez A, Marco F, Conde E, . Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000;85:894–895.
   PubMed Web of Science ®Google Scholar
• Aksoy S, Harputluoglu H, Kilickap S, . Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307–1312.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, . Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986–1992.
   PubMed Web of Science ®Google Scholar
• Foá R, Di Rocco A, Van Hazel G, . Maintenance rituximab every 2 months for 2 years is effective and well tolerated in patients with follicular lymphoma with both standard or rapid infusion: updated results from the phase IIIb MAXIMA study. Blood 2010;116(Suppl. 1): Abstract 3945.
   Google Scholar